摘要
目的 探讨Graves病(GD)患者放射性131碘治疗前后可溶性Fas(sFas)的水平变化及其临床意义。方法 采用免疫酶联分析法(ELISA法),测定50例GD患者放射性131碘治疗前后外周血sFas的水平变化。结果 GD患者外周血sFas水平(3.41±1.58ng/ml)显著高于正常对照组(0.85±0.42ng/ml,P<0.001),放射性131碘治疗3个月后,血清sFas水平(1.95±2.03ng/ml)较治疗前显著下降(P<0.001),但仍高于正常水平(P<0.001)。sFas水平与FT3、FT4呈显著正相关(P<0.01),而与T3、T4、TSH、甲状腺球蛋白抗体(TGA-Ab)、甲状腺过氧化物酶抗体(TPO-Ab)、甲状腺摄碘率无明显相关性。结论 sFas异常增加参与GD发病过程,放射性131碘治疗GD具有免疫调节功能。
Objective To investigate the clinical significance of the serum sFas change in patients with radio-active 131I-treated Graves' disease. Method The serum concentration of sFas was measured by enzyme-linked immunosorbent assay. Results The serum concentration of sFas(3. 41 ± 1. 58ng/ml)was significantly increased inn untreated GD compared with age-matched control subjects (0. 85±0. 42ng/ml,P<0. 001). The serum sFas level(1. 95±2. 03ng/ml)tended to decrease after the medication of radio-active 131 I for 3 months, but still higher than that of the normal controls. The concentration of serum sFas was significantly correlated with FT3 ,FT4 (P<0. 001) ,but not with the other clinical parameters(T3 ,T4 ,TSH,TGA-Ab,TPOAb,or 131I uptake). Conclusion These data suggest that sFas may play a role in the pathogensis of GD and radio-active 131I therapy has immunomodu-latory effect on this disease.
出处
《江苏医药》
CAS
CSCD
北大核心
2003年第3期164-166,共3页
Jiangsu Medical Journal